The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR).
Primo Lara
No relevant relationships to disclose
Benjamin Ely
No relevant relationships to disclose
David I. Quinn
Consultant or Advisory Role - Bayer; Dendreon; Medivation; Novartis; Oncogenex; Pfizer
Catherine M. Tangen
No relevant relationships to disclose
Erik Gertz
No relevant relationships to disclose
Philip C. Mack
No relevant relationships to disclose
Przemyslaw Twardowski
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen
Maha Hussain
No relevant relationships to disclose
Ian Murchie Thompson
No relevant relationships to disclose
Marta Van Loan
No relevant relationships to disclose